Connect with us


Hillary Clinton Tweets, IBB Drops



Multiple news outlets reported Hillary Clinton is cracking down on Biotech. But her anger was focused on one company in particular – Mylan, the maker of EpiPens.

Hillary Clinton Tweets, IBB Drops

With One Single Tweet, Hillary Clinton Caused The iShares NASDAQ Biotechnology ETF (IBB) To Have Its Worst Day Since June 27th.

From 2007 to 2015, Mylan raised EpiPen wholesale prices from $56.64 to $317.82, an increase of 461 percent. During the same time frame, the company’s CEO, Heather Bresch, saw her total compensation increase from $2,453,456 to $18,931,068, or 671 percent.

Mylan continuously raised EpiPen prices, even raising EpiPen prices 15 percent  every other quarter from 2013-2016. Bloomberg reported EpiPens provided 40 percent of the company’s profits in 2014. As a result, Mylan saw its stock price more than triple, from $13.29 in 2007 to a high of $47.59 in 2016.

EpiPens are filled with epinephrine, a hormone which ends an allergy attack. Because epinephrine is an unstable hormone; EpiPens need to be replaced regularly so that the dosage inside remains correct. Most people with severe allergies keep an EpiPen around at all times as a safety precaution. As a result of that, six years ago, the US Food and Drug Administration ruled that the devices have to be sold in packs of two because some children need more than one at a time to fight an allergy attack.

Clinton called the price hit “outrageous” and “the latest troubling example of a company taking advantage of its consumers” in a statement. She then tweeted

And Mylan’s stock saw a -5.41% drop. The IBB saw a 3.36% drop from where it was resting, And other Biotech companies, such as  Insys also saw their stock dip. In addition, multiple senators have joined Clinton from both sides of the aisle. Lawmakers are calling for investigations into the price increase of EpiPens, including: Republican Senator Chuck Grassley, chairman of the Senate Judiciary Committee, Senator Amy Klobuchar, the top Democrat on the committee's antitrust subcommittee, Republican Senator Susan Collins

Biotech stocks will continue to dip. If Clinton wins the presidency, expect to see Biotech companies come under tighter regulation, and see their shares drop significantly.

Read this next: Disney Hits Newest Deal Out Of The Park

Featured image via Forbes

The statements, views, and opinions of any article, contribution, editorial, or advertisement in this publication are not necessarily those of The Capitalist or its editorial staff, and are not considered an endorsement, sponsorship, or recommendation of any referenced product, service, issuer, or groups of issuers.

This publication provides general information about certain subjects, and should not be construed or taken as advice (legal, financial, investment, tax, or otherwise).  Do not construe or take any information in this publication as a solicitation, offer, opinion, or recommendation to buy or sell any securities, bonds, or other financial instruments or to provide any legal, financial, investment, tax, or other advice or service about the suitability or profitability of any financial instruments or investments.

The Capitalist disclaims any liability for the accuracy of or your reliance on any statements, views, opinions, or information in this publication.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Continue Reading

Copyright © 2023 The Capitalist. his copyrighted material may not be republished without express permission. The information presented here is for general educational purposes only. MATERIAL CONNECTION DISCLOSURE: You should assume that this website has an affiliate relationship and/or another material connection to the persons or businesses mentioned in or linked to from this page and may receive commissions from purchases you make on subsequent web sites. You should not rely solely on information contained in this email to evaluate the product or service being endorsed. Always exercise due diligence before purchasing any product or service. This website contains advertisements.


Is THE newsletter for…


Stay up-to-date with the latest kick-ass interviews, podcasts, and more as we cover a wide range of topics, in the world of finance and technology. Don't miss out on our exclusive content featuring expert opinions and market insights delivered to your inbox 100% FREE!